ESC 365 - A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome

ESC2024 Premium Access

A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome

Session: Smaller trials, trial updates, and other studies on lipid therapy

Topic: Drug therapy

Speaker: Professor G. Watts (Perth, AU)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Professor Gerald Watts

University of Western Australia, Perth (Australia)

2 presentations

0 follower

4 more presentations in this session

Apolipoprotein A-I infusions and cardiovascular outcomes in patients with acute myocardial infarction and hyperlipidemia

Speaker: Doctor C. Gibson (Boston, US)

Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial

Speaker: Doctor Y. Kang (Boston, US)

Alternative LDL cholesterol lowering strategy vs. high-intensity statin strategy: An individual patient data meta-analysis from the randomized RACING and LODESTAR trials

Speaker: Professor M. Hong (Seoul, KR)

ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction

Speaker: Doctor G. Chi (Boston, US)

Access the full session

Smaller trials, trial updates, and other studies on lipid therapy

Speakers: Professor G. Watts, Doctor C. Gibson, Doctor Y. Kang, Professor M. Hong, Doctor G. Chi

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources